Is This "Strong Buy" Health Insurance Company A Bargain?

NYSE: ELV | Elevance Health News, Ratings, and Charts

ELV – Healthcare company Elevance Health (ELV) reported solid revenue growth in the last reported quarter. While the stock trades at a discount to its peers, analysts expect the company’s financials to improve. So, let’s evaluate if it would be wise to buy the stock now. Read on…

Elevance Health Inc. (ELV - Get Rating) is a health benefits company. It assists consumers, families, and communities along the care journey by linking them to the care, support, and resources they need to live healthy lives. It provides medical, digital, pharmaceutical, behavioral, clinical, and care solutions to about 118 million people.

Originally known as Anthem, Inc., the firm changed its name to Elevance Health Inc. in June 2022.

In terms of forward Non-GAAP P/E, the stock is currently trading at 16.97x, 12.6% lower than the industry average of 19.43x. Also, its forward EV/Sales of 0.88x is 75.9% lower than the industry average of 3.67x. Moreover, ELV’s forward Price/Sales of 0.76x is 82.9% lower than the industry average of 4.47x.

The stock has gained 26.6% over the past year and 29.2% over the past nine months to close its last trading session at $485.98. The company is well-positioned to gain in the ever-evolving healthcare industry through its various strategic operational advancements.

Here’s what could shape ELV’s performance in the near term:

Strategic Acquisition

In May, ELV (formerly known as Anthem Inc.) announced the completion of its acquisition of Integra Managed Care, a New York-based Managed Long-Term Care Plan that assists persons with long-term care requirements and disabilities in living securely and independently in their own homes.

“We’re pleased to complete this acquisition and work alongside our new colleagues as we continue to grow our Medicaid business and enhance the healthcare experience for all of our members,” said Felicia Norwood, Executive Vice President of Anthem’s Government Business Division.

Robust Financials

During the first quarter ended March 31, 2022, ELV’s total revenue increased 17.6% year-over-year to $38.09 billion. The company’s net income grew 7.7% from the year-ago value to $1.79 billion, while its EPS amounted to $244.4.

Its cash and cash equivalents came in at $6.16 billion, representing an increase of 26.3% for the three months ended March 31, 2022.

Impressive Growth Prospects

Street expects ELV’s revenues and EPS to rise 12.3% and 10.2% year-over-year to $153.78 billion and $28.64, respectively, in fiscal 2022. In addition, ELV’s EPS is expected to rise at a 12.6% CAGR over the next five years.

Moreover, the company has an impressive earnings surprise history, as it topped Street EPS estimates in all of the trailing four quarters.

Consensus Rating and Price Target Indicate Potential Upside

Of the 20 Wall Street analysts that rated ELV, 16 rated it Buy, and four rated it Hold. The 12-month median price target of $568.40 indicates a 16.9% potential upside. The price targets range from a low of $335.00 to a high of $642.00.

POWR Ratings Reflect Solid Prospects

ELV has an overall grade of A, equating to a Strong Buy rating in our proprietary POWR Ratings system. The POWR Ratings are calculated considering 118 different factors, with each factor weighted to an optimal degree.

Our proprietary rating system also evaluates each stock based on eight different categories. ELV has a B grade for Quality, Growth, and Value. ELV’s solid earnings and revenue growth potential is consistent with the Quality and Growth grade. In addition, the company’s lower-than-industry multiples are in sync with the Value grade.

Of the 11 stocks in the A-rated Medical – Health Insurance industry, ELV is ranked #1.

Beyond what I stated above, we have graded ELV for Sentiment, Stability, and Momentum. Get all ELV ratings here.

Bottom Line

ELV has gained 29.3% over the past month. Its impressive growth attributes and continued effort to boost its operational capabilities should enable it to witness robust growth in the near term. In addition, as the stock is currently trading at a significant discount to its peers, we think it could be wise to scoop up its shares now.

How Does Elevance Health Inc. (ELV) Stack Up Against its Peers?

ELV has an overall POWR Rating of A, which equates to a Strong Buy rating.  Check out these other stocks within the same industry with A (Strong Buy) ratings: Cigma Corp. (CI - Get Rating), UnitedHealth Group Inc. (UNH - Get Rating), and Centene Corp. (CNC - Get Rating).

Want More Great Investing Ideas?

3 Stocks to DOUBLE This Year


ELV shares were trading at $468.83 per share on Tuesday morning, down $17.15 (-3.53%). Year-to-date, ELV has declined %, versus a -20.36% rise in the benchmark S&P 500 index during the same period.


About the Author: Pragya Pandey


Pragya is an equity research analyst and financial journalist with a passion for investing. In college she majored in finance and is currently pursuing the CFA program and is a Level II candidate. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
ELVGet RatingGet RatingGet Rating
CIGet RatingGet RatingGet Rating
UNHGet RatingGet RatingGet Rating
CNCGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


Why Are Stocks Floating Higher?

Why are stocks breaking above 6,000 once again? When will they make news highs? And what is an investor to do now? Seasoned investor Steve Reitmeister shares his thoughts in this updated commentary.

How is the Stock Market Like a Helium Balloon?

Stocks have finally broke above 6,000 for the S&P 500 (SPY). The more important question is what comes next? Steve Reitmeister provides his answer in his latest market commentary.

Has the Bull Market Run Out of Steam?

It seems the S&P 500 (SPY) advance has stalled and cant crack above strong resistance at 6,000. Why is that happening? And what happens next? Read on for the answers...

Investors Remain “Cautiously Optimistic”

The S&P 500 (SPY) has made great advances since the lows of early April. Yet seem to be stuck under resistance at 6,000. What happens next depends on tariff talks. So let’s talk about the latest news on that front.

Bull Market Til Proven Otherwise

The phrase that paid for investors in 2025 was “Bull market til proven otherwise” Steve Reitmeister explains why in his latest market update and preview of top stock picks.

Read More Stories

More Elevance Health (ELV) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All ELV News